Maze Therapeutics, Inc. (MAZE) Misses Q2 EPS by 15c
Tweet
Share
E-mailGet Alerts MAZE Hot Sheet
Join SI Premium – FREE
Maze Therapeutics, Inc. (NASDAQ: MAZE) reported Q2 EPS of ($0.77), $0.15 worse than the analyst estimate of ($0.62).
For earnings history and earnings-related data on Maze Therapeutics, Inc. (MAZE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Parsons wins $665M Army contract for support services
- XP Inc. (XP) Tops Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
